Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026
EASD 2026 28 September - 2 October 2026

Semaglutide improves cardiometabolic risk factors in menopausal women living with MASH: a post hoc analysis of the ESSENCE trial part 1

Authors :

L.L. Gluud1, M.F. Abdelmalek2, M.T. Arias-Loste3, B. Demirel4, G. Frühbeck5, A. Geerts6, L. Ladrón de Guevara7, E. Janczewska8, O.K. Jeppesen4, C. Oliveira9, M.E. Rinella10, G. Sebastiani11, A. Trifan12, T.C. Vestergaard4, E. Bugianesi13 
Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Download poster (.pdf)
Keywords
MASH
Congress short oral presentation
GLP-1 RA
Semaglutide
PHASE 3 (RCT)